Neurocrine Biosciences | NBIX - Stock



Neurocrine Biosciences reported $56.9M in Stock for its fiscal quarter ending in June of 2025.


Stock Change Date
AbbVie USD 4.53B 345M Mar/2025
Acadia Pharmaceuticals USD 26.12M 3.18M Jun/2025
Agios Pharmaceuticals USD 30.85M 1.24M Jun/2025
ALKERMES USD 191.92M 8.49M Jun/2025
Alnylam Pharmaceuticals USD 71.69M 6.11M Jun/2025
Amgen USD 6.58B 146M Jun/2025
Biogen USD 2.27B 400K Jun/2025
BioMarin Pharmaceutical USD 1.34B 65.32M Jun/2025
Cytokinetics 0 0 Dec/2023
Dynavax Technologies USD 75.69M 1.28M Jun/2025
Exelixis USD 23.48M 1.37M Jun/2025
Gilead Sciences USD 1.83B 66M Jun/2025
Halozyme Therapeutics USD 181.5M 16.64M Jun/2025
Incyte USD 83.42M 19.45M Jun/2025
Ionis Pharmaceuticals USD 8.48M 3.02M Jun/2025
Neurocrine Biosciences USD 56.9M 2.2M Jun/2025
Pfizer USD 11.67B 817M Jun/2025
Regeneron Pharmaceuticals USD 3.21B 760.7M Jun/2025
Repligen USD 153.11M 10.15M Mar/2025
Sarepta Therapeutics USD 994.04M 52.6M Jun/2025
Teva Pharmaceutical Industries USD 3.5B 250M Jun/2025
Ultragenyx Pharmaceutical USD 46.5M 467K Jun/2025
Vertex Pharmaceuticals USD 1.5B 139.6M Jun/2025